PATENT CLAIM ANALYSIS

Application Number: 16083413
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "718000"]

Abstract:
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and/or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and/or slowing down brain atrophy in a human subject in need thereof.

Claim (Index 24):
The method according to  claim 23 , wherein vitamin C is administered in an amount of 50 to 150 mg per 100 g of the composition or per day.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 97.0
- Lexical Diversity: 1.69841
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15115487', '14784838', '15417943', '14005098', '14355197']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7388179694944561
- 35 USC 102 Novelty (BERT): 0.5284286837997274
- Combined Prediction Score: 0.7177790409249832
- Mean Citation Score: 309.52489
- Max Citation Score: 322.7444799999999
- Similarity Product: 231.23804671592703

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test